Mobile

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) Sperimentazio...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-012152-24

A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) Sperimentazione di ABT-263 in associazione con Rituximab dose-intensive o di Rituximab dose-intensive da solo in pazienti con leucemia linfocitica cronica (CLL) a cellule B non precedentemente trattati

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of ABT-263 when given according to two different regimens in combination with doseintense rituximab in previously untreated patients with B-cell CLL, as measured by progression-free survival (PFS) based on investigator assessments. Determinare l’efficacia di ABT-263 somministrato secondo due differenti regimi in combinazione con rituximab “dose-intense” in soggetti non precedentemente trattati affetti da LLC a cellule B, misurata come sopravvivenza libera da progressione (PFS) basata su valutazione dello sperimentatore.

Critère d'inclusion

  • B-cell Chronic Lymphocytic Leukemia (CLL),Leucemia linfocitica cronica a cellule B (CLL)

Liens